mProX™ Human KCNQ2 Stable Cell Line

Product Information

Target Protein

KCNQ2

Target Family

Kv7

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

Ion Channel Cell Lines

Target Research Area

Auditory and Otology Research; CNS Research

Related Diseases

Developmental And Epileptic Encephalopathy; Seizures, Benign Familial Neonatal; Benign Familial Neonatal Epilepsy

Gene ID

3785

UniProt ID

O43526

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The KCNQ2 gene is a member of a broad gene family that codes for the production of potassium channels. A potassium channel's particular purpose is determined by the proteins that make up the channel and where in the body it is located. Potassium ions are transported out of brain nerve cells via channels that are produced using the KCNQ2 protein. These channels convey an M-current, a specific kind of electrical signal that stops a neuron from sending impulses to neighboring neurons. The M-current makes sure the neuron is not excitable or active all the time. A channel can be formed by four of the KCNQ2 gene's alpha subunits. However, in order to generate a functioning potassium channel, the alpha subunits of the KCNQ2 gene can also connect with those of the KCNQ3 gene to produce a significantly stronger M-current. The customized KCNQ2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Timothy

I customized the mouse KCNQ2 cell line for my research. Jan 12 2022

chat Verified Customer

chat Thomas

I purchased the Human KCNQ2 Stable Cell Line for high-throughput drug screening. Nov 15 2022

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Heterologous expression of KCNQ2-R581Q.

Left: voltage pulse step procedure and transfection approach. Middle: Automated patch-clamp recording of average XE-991-sensitive whole-cell currents normalized by membrane capacitance. KCNQ3-expressing CHO-K1 cells were transiently transfected with R581Q (10 µg) plus wild-type KCNQ2 or wild-type KCNQ2 to simulate the heterozygous condition (bottom) or with wild-type KCNQ2 or R581Q variant to recapitulate a homozygous state (top).

Ref: Simkin, Dina, et al. "Dyshomeostatic modulation of Ca2+-activated K+ channels in a human neuronal model of KCNQ2 encephalopathy." Elife 10 (2021): e64434.

Pubmed: 33544076

DOI: 10.7554/eLife.64434

Research Highlights

Early onset epileptic encephalopathies and benign seizure disorders are also included in the group of KCNQ2-related illnesses. Patients in the latter category, in particular, experience developmental delay and seizures that are resistant to common antiepileptic medications. There are few systematic data on therapy responses in KCNQ2 associated epilepsy in bigger cohorts, which is concerning given the hope of customized pharmacological methods to treat the enormous number of hereditary channelopathies that have recently been discovered.
Kuersten, M., et al. "Antiepileptic therapy approaches in KCNQ2 related epilepsy: a systematic review." European Journal of Medical Genetics 63.1 (2020): 103628.
Pubmed: 30771507 DOI: 10.1016/j.ejmg.2019.02.001

In addition to being therapeutic targets for neurological and neuropsychiatric disorders, KCNQ2 and KCNQ3 channels are linked to a number of neurodevelopmental abnormalities.
Soh, Heun, et al. "KCNQ2 and KCNQ5 form heteromeric channels independent of KCNQ3." Proceedings of the National Academy of Sciences 119.13 (2022): e2117640119.
Pubmed: 35320039 DOI: 10.1073/pnas.2117640119